CL2018002559A1 - Composiciones y métodos para tratar artritis reumatoide. - Google Patents

Composiciones y métodos para tratar artritis reumatoide.

Info

Publication number
CL2018002559A1
CL2018002559A1 CL2018002559A CL2018002559A CL2018002559A1 CL 2018002559 A1 CL2018002559 A1 CL 2018002559A1 CL 2018002559 A CL2018002559 A CL 2018002559A CL 2018002559 A CL2018002559 A CL 2018002559A CL 2018002559 A1 CL2018002559 A1 CL 2018002559A1
Authority
CL
Chile
Prior art keywords
rheumatoid arthritis
compositions
methods
treat rheumatoid
arthritis
Prior art date
Application number
CL2018002559A
Other languages
English (en)
Spanish (es)
Inventor
Deborah Bauer
Alexander Boddy
Neil Graham
Yong Lin
Janie Parrino
Rahul Patel
Adelsberg Janet Van
Hoogstraen Hubert Van
Original Assignee
Sanofi Biotechnology Francia Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16305253.3A external-priority patent/EP3216461A1/en
Application filed by Sanofi Biotechnology Francia Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology Francia Regeneron Pharmaceuticals Inc
Publication of CL2018002559A1 publication Critical patent/CL2018002559A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2018002559A 2016-03-07 2018-09-07 Composiciones y métodos para tratar artritis reumatoide. CL2018002559A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305253.3A EP3216461A1 (en) 2016-03-07 2016-03-07 Compositions and methods for treating rheumatoid arthritis
EP16170664 2016-05-20
EP16306111 2016-09-05

Publications (1)

Publication Number Publication Date
CL2018002559A1 true CL2018002559A1 (es) 2019-03-01

Family

ID=58387910

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002559A CL2018002559A1 (es) 2016-03-07 2018-09-07 Composiciones y métodos para tratar artritis reumatoide.

Country Status (18)

Country Link
US (1) US20190100585A1 (enExample)
EP (1) EP3426295A1 (enExample)
JP (2) JP7166925B2 (enExample)
KR (2) KR20180114955A (enExample)
CN (1) CN109069642A (enExample)
AU (2) AU2017229364A1 (enExample)
BR (1) BR112018067851A2 (enExample)
CA (1) CA3016880A1 (enExample)
CL (1) CL2018002559A1 (enExample)
CR (1) CR20180465A (enExample)
EA (1) EA201892005A1 (enExample)
IL (2) IL308539A (enExample)
MX (2) MX2018010815A (enExample)
PH (1) PH12018501894A1 (enExample)
SG (2) SG11201807614SA (enExample)
TN (1) TN2018000312A1 (enExample)
TW (3) TW202419103A (enExample)
WO (1) WO2017155990A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2019105450A1 (zh) * 2017-11-30 2019-06-06 百奥泰生物制药股份有限公司 一种治疗il-6相关疾病的人源化抗体的液体制剂
KR20210049871A (ko) * 2018-08-29 2021-05-06 리제너론 파아마슈티컬스, 인크. 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물
TWI860325B (zh) * 2019-01-31 2024-11-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
BR112021021077A2 (pt) * 2019-04-24 2021-12-14 E Zilberstein Moshe Métodos de diagnóstico e tratamento de artrite reumatoide
MX2021014892A (es) * 2019-06-04 2022-06-27 Sanofi Biotechnology Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide.
WO2023020563A1 (en) * 2021-08-18 2023-02-23 Bio-Thera Solutions, Ltd. Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2385745C (en) * 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
CA2930615C (en) * 2013-11-22 2023-04-04 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same

Also Published As

Publication number Publication date
JP7745529B2 (ja) 2025-09-29
TN2018000312A1 (en) 2020-01-16
TW202419103A (zh) 2024-05-16
IL261515B2 (en) 2024-04-01
KR20230093522A (ko) 2023-06-27
WO2017155990A1 (en) 2017-09-14
BR112018067851A2 (pt) 2019-02-05
JP7166925B2 (ja) 2022-11-08
CR20180465A (es) 2019-03-04
AU2024203011A1 (en) 2024-07-11
EP3426295A1 (en) 2019-01-16
PH12018501894A1 (en) 2019-05-15
KR20180114955A (ko) 2018-10-19
JP2019507775A (ja) 2019-03-22
CA3016880A1 (en) 2017-09-14
NZ746988A (en) 2023-10-27
IL261515A (en) 2018-10-31
JP2023011711A (ja) 2023-01-24
SG10202012182YA (en) 2021-01-28
IL261515B1 (en) 2023-12-01
TW201808993A (zh) 2018-03-16
TW202239767A (zh) 2022-10-16
IL308539A (en) 2024-01-01
SG11201807614SA (en) 2018-10-30
AU2017229364A1 (en) 2018-10-25
TWI819435B (zh) 2023-10-21
TWI747885B (zh) 2021-12-01
EA201892005A1 (ru) 2019-02-28
MX2023014841A (es) 2024-01-15
US20190100585A1 (en) 2019-04-04
MX2018010815A (es) 2019-01-10
CN109069642A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
CL2018002559A1 (es) Composiciones y métodos para tratar artritis reumatoide.
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
MX388710B (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso.
DOP2019000056A (es) Anticuerpos anti-pd-1 y sus usos
MX2023005881A (es) Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
MX2022002959A (es) Anticuerpos anti-tigit y metodos de uso.
SA517381664B1 (ar) أجسام مضادة تستهدف مستقبل مقترن ببروتين وطرق استخدامها g
MX377190B (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
CR20160314A (es) Anticuerpos anti-cd3 y metodos de uso
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
ECSP14016994A (es) Anticuerpos cd47 y métodos de uso los mismos
MX380520B (es) Anticuerpos receptores de antitransferina y métodos de uso.
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
CO2019013718A2 (es) Anticuerpos anti-trkb
CO2021015660A2 (es) Métodos de diagnóstico y tratamiento de la artritis reuma-toide
MX2021015473A (es) Nuevo anticuerpo específico para cthrc1 y su uso.
AR117596A2 (es) Anticuerpos anti-cd3 y métodos de uso